Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3043594 covering methods to administer its proprietary mesenchymal stem cell therapy laromestrocel (LOMECEL-B) for treatment of aging-related frailty with inflammaging and for non-ischemic dilated cardiomyopathy (NIDCM).
The patent provides Longeveron with rights in Canada through 2037. The company cites prior Phase 1 and 2 studies that delivered positive initial results in aging-related frailty, including designed improvements in the six-minute walk test and physical functioning. The release emphasizes inflammaging links to frailty and notes MSCs have shown favorable changes in immunologic markers in vivo.
Positive
- Canadian patent No. 3043594 granted through 2037
- Patent covers laromestrocel use for frailty and NIDCM
- Prior Phase 1–2 studies showed positive initial results in frailty trials
Negative
- Patent rights described are limited to Canada only
- No regulatory approvals or commercialization plans disclosed
News Market Reaction – LGVN
On the day this news was published, LGVN gained 2.22%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.9% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $292K to the company's valuation, bringing the market cap to $13.44M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: NBY up 31.92%, while MTVA, SYBX, PULM, and EDSA are down, indicating stock-specific factors for LGVN rather than a broad biotech swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Conference participation | Positive | -1.2% | Executives speaking on cell therapy for heart failure at CVCT Forum. |
| Dec 02 | Patent grant | Positive | +2.2% | Canadian patent on laromestrocel for frailty and NIDCM to 2037. |
| Dec 01 | Clinical data update | Positive | -5.1% | Phase 2 CLEAR MIND MRI biomarker data showing reduced neuroinflammation. |
| Nov 19 | Conference poster | Positive | -4.0% | Laromestrocel Alzheimer’s data selected for CTAD 2025 poster presentation. |
| Nov 12 | Patent grant | Positive | -1.3% | U.S. patent on treating aging-related frailty with inflammaging using MSCs. |
Recent news flow has been mostly positive (patents, data, conferences), yet 4 of the last 5 events saw negative price reactions, suggesting a tendency for the stock to trade weakly around good news.
This announcement adds another intellectual property milestone to Longeveron’s recent stream of news. Over the past month, the company reported a new U.S. patent for aging-related frailty through 2038, MRI biomarker data from the CLEAR MIND Phase 2 Alzheimer’s study, and conference and poster presentations highlighting laromestrocel. A prior Canadian patent release on Dec 2, 2025 saw a modest 2.22% gain, while most other positive items, including data and IP updates, coincided with share price declines, underscoring muted market enthusiasm.
Market Pulse Summary
This announcement highlights expanded intellectual property protection in Canada for laromestrocel, covering aging-related frailty with inflammaging and non-ischemic dilated cardiomyopathy through 2037. It builds on prior U.S. patent wins and clinical signals from Phase 1 and 2 frailty studies and Alzheimer’s data. Investors may track future trial readouts, regulatory interactions, and how the company manages its limited cash runway and ATM capacity while advancing multiple indications.
Key Terms
mesenchymal stem cells medical
non-ischemic dilated cardiomyopathy medical
inflammaging medical
six-minute walk test medical
in vivo medical
AI-generated analysis. Not financial advice.
- The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathy
- Non-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantation
- No approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss
- Laromestrocel, a mesenchymal stem cell therapy, has delivered positive initial results across two clinical trials in aging-related frailty
MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Canadian Intellectual Property Office (CIPO) has granted a patent covering administration of laromestrocel (LOMECEL-B®), the Company’s proprietary mesenchymal stem cells (MSCs), for the treatment of patients with symptoms of aging-related frailty and also for the treatment of non-ischemic dilated cardiomyopathy (NIDCM).
Canadian Patent No. 3043594, entitled “Method of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity,” provides Longeveron with patent rights in Canada through 2037.
Aging-related frailty is a syndrome of multisystem physiological dysregulation occurring in older individuals which diminishes human healthspan. The symptoms of aging-related frailty include weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss. Many studies show a direct correlation between aging-related frailty and inflammation. Inflammaging has received considerable attention because it proposes a link between immune changes and a number of diseases and conditions (such as aging-related frailty) common in old age.
Longeveron has previously conducted Phase 1 and 2 studies in aging-related frailty designed to show improvements in the six-minute walk test and physical functioning for its lead MSC drug, laromestrocel.
Non-ischemic dilated cardiomyopathy (NIDCM) is a condition where the heart muscle becomes weakened and enlarged, negatively affecting its ability to pump blood effectively. NIDCM is a progressive disorder with no current cure, often leading to heart transplantation. In vivo administration of isolated MSCs has been shown to favorably alter several immunologic markers typically elevated in chronic inflammation. Restoration of immune competence has clinical relevance in patients who are of higher risk for co-morbid infectious disease.
About laromestrocel (LOMECEL-B®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to our endogenous biological repair mechanism. MSCs have been shown to perform a number of complex functions in the body, including the formation of new tissue. They also have been shown to respond to sites of injury or disease and secrete bioactive factors that are immunomodulatory and regenerative. We believe that laromestrocel may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
What did Longeveron (LGVN) announce on December 2, 2025?
What conditions does the LGVN patent cover for laromestrocel?
How long do Longeveron’s Canada patent rights last for LGVN?
Did Longeveron report clinical trial results for laromestrocel (LGVN)?
Does the LGVN announcement indicate regulatory approval for laromestrocel?
